SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-022721
Filing Date
2024-04-29
Accepted
2024-04-29 08:46:38
Documents
6
Period of Report
2024-06-12

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20022295x2_def14a.htm DEF 14A 549691
2 logo_gyre.jpg GRAPHIC 26811
3 ny20022295x2_pc01x1.jpg GRAPHIC 656089
4 ny20022295x2_pc02x1.jpg GRAPHIC 701124
5 ny20022295x2_pvp01.jpg GRAPHIC 144669
6 ny20022295x2_pvp02.jpg GRAPHIC 149456
  Complete submission text file 0001140361-24-022721.txt   2860843
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51173 | Film No.: 24886801
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)